ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintTitle ChevronIcon Twitter
Business

Sumitomo Dainippon Pharma eyes injectable retinal transplants

OSAKA -- Sumitomo Dainippon Pharma plans to develop an injectable stem cell treatment for a disorder that can cause vision loss, aiming to begin clinical trials as early as 2017.

     The Japanese drug company will work with the government-backed Riken research institute on a new cell transplantation technique for age-related macular degeneration, which afflicts more than 100 million patients worldwide and some 700,000 in Japan. The method will employ induced pluripotent stem cells, or iPS cells.

     Riken implanted a retinal sheet developed from a patient's own iPS cells into the same patient last September. That process, from initial extraction of cells to transplanting the sheet, takes about 10 months.

     Sumitomo Dainippon Pharma's treatment will use iPS cells from other patients and be administered via injection. This will simplify the process and slash the time needed, along with cutting costs.

     A venture in which Sumitomo Dainippon Pharma holds a 50% stake will set up an iPS cell cultivation facility in Kobe by the end of fiscal 2015. The company hopes to obtain marketing approval for the treatment in Japan as early as 2020.

     Sumitomo Dainippon Pharma will also consider developing injectable treatments for such other conditions as pigmentary retinal degeneration, Parkinson's disease and spinal cord injuries.

(Nikkei)

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends January 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more